Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11567-11573
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11567
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11567
What make differences in the outcome of adjuvant treatments for resected gastric cancer?
Toshifusa Nakajima, Department of Gastrointestinal Surgery, Cancer Institute Ariake Hospital, Tokyo 135-8550, Japan
Toshifusa Nakajima, The vice president, Japan Cancer Clinical Research Organization (JACCRO) Chuo-ku, Tokyo 104-0061, Japan
Masashi Fujii, Department of Surgery, Nihon University Surugadai Hospital, Tokyo 101-0062, Japan
Author contributions: Nakajima T and Fujii M performed research, and Nakajima T wrote the paper.
Correspondence to: Toshifusa Nakajima, MD, PhD, Department of Gastrointestinal Surgery, Cancer Institute Ariake Hospital, Japanese Foundation for Cancer Research. 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan. nakajima@jfcr.or.jp
Telephone: +81-3-35200111 Fax: +81-3-35700343
Received: October 23, 2013
Revised: November 26, 2013
Accepted: April 8, 2014
Published online: September 7, 2014
Revised: November 26, 2013
Accepted: April 8, 2014
Published online: September 7, 2014
Core Tip
Core tip: Recent positive results of adjuvant clinical trials for gastric cancer are attributed to new approaches different from previous negative trials. Inclusion of novel effective drug (S-1: ACTS-GC) and new combination of drugs (capecitabine and oxaliplatin: CLASSIC/Cisplatin and 5-fluorouracil: FNCLCC/FFCD), combination of chemotherapy and radiotherapy (SWOG INT0116), and combination of different timing (pre- and postoperative: MAGICC), might have contributed to yield positive results after curative D2 surgery. D2 surgery is going to be adopted as recommended treatment in Eastern and Western countries, and should be the baseline treatment to minimize the amount of residual tumor in future trials of adjuvant treatment.